Munich, Germany, 17 October 2011 - Genomatix is among the 41 partners of the BLUEPRINT epigenome consortium funded by the European Commission as a high impact project within its seventh framework program (FP7). Genomatix' contributions will be next generation sequencing data analysis and the development of an intuitive GUI to make the project's results easily accessible to researchers within and outside the consortium.
"To be part of, and to get substantial funding from this ambitious project, is a pleasant affirmation of our research and development efforts to provide high quality data analysis in a very usable way for biologists", says Dr. Martin Seifert, CEO of Genomatix. "We highly appreciate the European Commission's commitment to support SMEs in its current FP7 program, as it enables us to participate in a high-profile research project that will generate fascinating new insights into epigenomics. It is of direct relevance to our business, as it will help us to offer our customers an even broader biological data background for their research. This will improve the understanding of molecular processes and hence lead to better biomedical applications."
Dr. Korbinian Grote, product manager at Genomatix adds: "The BLUEPRINT epigenome project is a chance to work with high-quality epigenomics data from renowned institutions and labs from all over Europe. It will help us to further improve our existing line of next generation sequencing analysis products and will lead to the implementation of new ideas tailored towards the integration of epigenomic data into our interfaces and visualizations."
About BLUEPRINT:
In response to the call for a High Impact Initiative on the human epigenome, the BLUEPRINT consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and on their malignant leukaemic counterparts. Reference epigenomes will be generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by the International Human Epigenome Consortium (IHEC). The BLUEPRINT project has a total budget of almost 40 million euro and will receive 30 million euro funding from the EC-FP7-Cooperation-Health budget. The project started on October 1, 2011 and will run for 4.5 years.
For further information, please visit http://www.blueprint-epigenome.eu/
About Genomatix:
Genomatix Software GmbH is one of the world's leading suppliers of technologies to analyze and interpret genomic data. Headquartered in Munich (Germany), Genomatix has a global presence by representations in Ann Arbor, MI (USA), Paris (France), London (UK) and Tokyo (Japan). Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have all needed data content and a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 120 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
For further information, please visit http://www.genomatix.com